Unknown

Dataset Information

0

Catalase-Functionalized Iron Oxide Nanoparticles Reverse Hypoxia-Induced Chemotherapeutic Resistance.


ABSTRACT: Intratumoral hypoxia is a major contributor to multiple drug resistance (MDR) in cancer, and can lead to poor prognosis of patients receiving chemotherapy. Development of an MDR-inhibitor that mitigates the hypoxic environment is crucial for cancer management and treatment. Reported is a biocompatible and biodegradable catalase-conjugated iron oxide nanoparticle (Cat-IONP) capable of converting reactive oxygen species to molecular oxygen to supply an oxygen source for the hypoxic tumor microenvironment. Cat-IONP demonstrates initial enzymatic activity comparable to free catalase while providing a nearly threefold increase in long-term enzymatic activity. It is demonstrated that Cat-IONP significantly reduces the in vitro expression of hypoxia-inducible factors at the transcription level in a breast cancer cell line. Co-treatment of Cat-IONP and paclitaxel (PTX) significantly increases the drug sensitivity of hypoxic-cultured cells, demonstrating greater than twofold and fivefold reduction in cell viability in comparison to cells treated only with 80 and 120 × 10-6 m PTX, respectively. These findings demonstrate the ability of Cat-IONP to act as an MDR-inhibitor at different biological levels, suggesting a promising strategy to combat cancer-MDR and to optimize cancer management and treatment outcomes.

SUBMITTER: Yen TY 

PROVIDER: S-EPMC6919328 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Catalase-Functionalized Iron Oxide Nanoparticles Reverse Hypoxia-Induced Chemotherapeutic Resistance.

Yen Tin-Yo TY   Stephen Zachary R ZR   Lin Guanyou G   Mu Qingxin Q   Jeon Mike M   Untoro Stela S   Welsh Parker P   Zhang Miqin M  

Advanced healthcare materials 20190926 20


Intratumoral hypoxia is a major contributor to multiple drug resistance (MDR) in cancer, and can lead to poor prognosis of patients receiving chemotherapy. Development of an MDR-inhibitor that mitigates the hypoxic environment is crucial for cancer management and treatment. Reported is a biocompatible and biodegradable catalase-conjugated iron oxide nanoparticle (Cat-IONP) capable of converting reactive oxygen species to molecular oxygen to supply an oxygen source for the hypoxic tumor microenvi  ...[more]

Similar Datasets

| S-EPMC9610745 | biostudies-literature
| S-EPMC4409571 | biostudies-literature
| S-EPMC4427608 | biostudies-literature
| S-EPMC6304157 | biostudies-literature
| S-EPMC7026144 | biostudies-literature
| S-EPMC4675334 | biostudies-literature
| S-EPMC8467872 | biostudies-literature
| S-EPMC5763551 | biostudies-other
| S-EPMC3276591 | biostudies-literature
| S-EPMC6044893 | biostudies-literature